Keywords: geneva, returns, drug, rights, andrx, generics, manufacturer
Geneva returns drug rights to Andrx
Article | 25 October 2001
US generics manufacturer Andrx has terminated a 1999 agreement withNovartis subsidiary Geneva Pharmaceuticals which granted the latter marketing rights to a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
